CPIX Stock Overview A specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Cumberland Pharmaceuticals Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Cumberland Pharmaceuticals Historical stock prices Current Share Price US$2.51 52 Week High US$3.05 52 Week Low US$1.04 Beta 0.29 1 Month Change 136.79% 3 Month Change 102.42% 1 Year Change 42.61% 3 Year Change -46.14% 5 Year Change -51.26% Change since IPO -85.09%
Recent News & Updates
New major risk - Share price stability Dec 10
Cumberland Pharmaceuticals Inc. Announces FDA Approves Supplemental New Drug Application (sNDA) for Its Acetadote (N-Acetylcysteine for Injection) Product Dec 10
Third quarter 2024 earnings released: US$0.11 loss per share (vs US$0.073 loss in 3Q 2023) Nov 10
Cumberland Pharmaceuticals Announces New Study Compares Caldolor® (ibuprofen injection) to Ketorolac Nov 06
Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt? Nov 04
Cumberland Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 07, 2024 Nov 01 See more updates
New major risk - Share price stability Dec 10
Cumberland Pharmaceuticals Inc. Announces FDA Approves Supplemental New Drug Application (sNDA) for Its Acetadote (N-Acetylcysteine for Injection) Product Dec 10
Third quarter 2024 earnings released: US$0.11 loss per share (vs US$0.073 loss in 3Q 2023) Nov 10
Cumberland Pharmaceuticals Announces New Study Compares Caldolor® (ibuprofen injection) to Ketorolac Nov 06
Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt? Nov 04
Cumberland Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 07, 2024 Nov 01
Second quarter 2024 earnings released: US$0.077 loss per share (vs US$0.061 profit in 2Q 2023) Aug 07
Cumberland Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 31
First quarter 2024 earnings released: US$0.14 loss per share (vs US$0.013 profit in 1Q 2023) May 08
Cumberland Pharmaceuticals Inc. to Report Q1, 2024 Results on May 07, 2024 May 01 Cumberland Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $5.8 million. Mar 21
New minor risk - Share price stability Mar 15
Cumberland Pharmaceuticals Inc., Annual General Meeting, Apr 23, 2024 Mar 14
Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt? Mar 07
Full year 2023 earnings released: US$0.44 loss per share (vs US$0.38 loss in FY 2022) Mar 06
Cumberland Pharmaceuticals Inc. to Report Fiscal Year 2023 Results on Mar 05, 2024 Feb 28
Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Prospects Need A Boost To Lift Shares Jan 09
New minor risk - Shareholder dilution Dec 18
Third quarter 2023 earnings released: US$0.073 loss per share (vs US$0.028 loss in 3Q 2022) Nov 10
Cumberland Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 07, 2023 Nov 01 Cumberland Pharmaceuticals Inc. Announces New Antimicrobial Agents and Chemotherapy Detaining the Results of the First Clinical Study Investigating the Safety and Pharmacokinetics of Vibativ®? Injection in Children 2 to 17 Years of Age
New minor risk - Share price stability Oct 08
Why Investors Shouldn't Be Surprised By Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) Low P/S Oct 02
Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt? Aug 10
Second quarter 2023 earnings released: EPS: US$0.061 (vs US$0.091 loss in 2Q 2022) Aug 09
Cumberland Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 08, 2023 Aug 03
Cumberland Pharmaceuticals Inc. Announces the Publication of Positive Results from Clinical Study Investigating the Safety and Pharmacokinetics of Caldolor in Newborn Infants, Published in the Journal Pediatric Drugs Jun 27
Cumberland Pharmaceuticals Inc. Announces FDA Clearance of IND for New Treatment of Idiopathic Pulmonary Fibrosis May 24
U.S. Food and Drug Administration Approves Cumberland Pharmaceuticals Inc.'s Expanded Lab Labulation for Caldolor May 16
First quarter 2023 earnings released: EPS: US$0.013 (vs US$0.094 loss in 1Q 2022) May 10
Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Have A Healthy Balance Sheet? Mar 18
Full year 2022 earnings released: US$0.38 loss per share (vs US$0.37 loss in FY 2021) Mar 08
Cumberland Pharmaceuticals Inc. Announces Demise of Joey A. Jacobs, Member of Board of Directors Jan 19
Cumberland Pharmaceuticals Inc. Announces Approval of Supplemental New Drug Application from U.S. Food and Drug Administration Dec 13
Third quarter 2022 earnings released: US$0.028 loss per share (vs US$0.10 loss in 3Q 2021) Nov 19
Third quarter 2022 earnings released: US$0.028 loss per share (vs US$0.10 loss in 3Q 2021) Nov 10
Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt? Nov 02
Cumberland Pharmaceuticals Inc. to Report Q3, 2022 Results on Nov 08, 2022 Nov 02
Second quarter 2022 earnings released: US$0.091 loss per share (vs US$0.049 profit in 2Q 2021) Aug 11
Cumberland Pharmaceuticals Inc. to Report Q2, 2022 Results on Aug 09, 2022 Aug 03
Cumberland Pharmaceuticals Appoints Martin Brown Jr. to Its Board of Directors Jul 21
Calculating The Fair Value Of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Jul 20
Cumberland Pharmaceuticals Appoints Martin Brown Jr. to Its Board of Directors Jul 20
Cumberland Pharmaceuticals Inc. Announces Executive Changes Jun 05
First quarter 2022 earnings: EPS and revenues exceed analyst expectations May 12
Cumberland Pharmaceuticals Inc. to Report Q1, 2022 Results on May 10, 2022 May 04
Insufficient new directors Apr 27
Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Too Much Debt? Apr 15
Tabuk and Cumberland Partner to Bring Innovative Antibiotic with Life-Saving Potential to Middle East Apr 01
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 10
Cumberland Pharmaceuticals Inc. to Report Fiscal Year 2021 Results on Mar 08, 2022 Mar 03
Now 22% undervalued Jan 14
Cumberland Pharmaceuticals Inc. (NasdaqGS:CPIX) acquired SANCUSO from Kyowa Kirin, Inc. for $17 million. Jan 06
Checking In On Cumberland Pharmaceuticals Jan 04
Cumberland Pharmaceuticals Inc. Receives FDA Approval for Expanded Labeling for Caldolor® Dec 01
Third quarter 2021 earnings released: US$0.10 loss per share (vs US$0.083 loss in 3Q 2020) Nov 13
Health Check: How Prudently Does Cumberland Pharmaceuticals (NASDAQ:CPIX) Use Debt? Nov 09
Consensus forecasts updated Aug 17
Second quarter 2021 earnings released: EPS US$0.049 (vs US$0.11 loss in 2Q 2020) Aug 12
Cumberland Pharmaceuticals Inc.(NasdaqGS:CPIX) dropped from Russell Microcap Growth Index Jun 28
Cumberland Pharmaceuticals Inc. Releases a Series of Case Reports Describing the Effectiveness of Vibativ® (Telavancin) in Treating Secondary Bacterial Infections in COVID-19 Patients Jun 22
Consensus EPS estimates increase to -US$0.18 May 13
We Think Some Shareholders May Hesitate To Increase Cumberland Pharmaceuticals Inc.'s (NASDAQ:CPIX) CEO Compensation Apr 21
Cumberland Pharmaceuticals Inc., Annual General Meeting, Apr 27, 2021 Mar 16
Full year 2020 earnings released: US$0.43 loss per share (vs US$0.23 loss in FY 2019) Mar 11
Revenue beats expectations Mar 11
Cumberland Pharmaceuticals Inc. to Report Q4, 2020 Results on Mar 09, 2021 Mar 03
Is Cumberland Pharmaceuticals (NASDAQ:CPIX) Using Debt In A Risky Way? Feb 13
New 90-day high: US$3.31 Feb 09
New 90-day high: US$3.22 Jan 14
Analysts update estimates Nov 20
One Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Analyst Just Cut Their EPS Forecasts Nov 19
Cumberland Pharmaceuticals Inc. Announces the Launch of Reditrex® (Methotrexate) Injection Nov 18
Revenue beats expectations, earnings disappoint Nov 18
Third quarter 2020 earnings released: US$0.083 loss per share Nov 18
Revenue beats expectations, earnings disappoint Nov 12
Third quarter 2020 earnings released: US$0.083 loss per share Nov 12
Cumberland Pharmaceuticals Inc. 2020 Q3 - Results - Earnings Call Presentation Nov 11
Cumberland Pharmaceuticals Inc. to Report Q3, 2020 Results on Nov 10, 2020 Nov 05
New 90-day low: US$2.94 Nov 03
New 90-day low: US$3.07 Oct 15
Cumberland Pharmaceuticals Inc. to Report Q4, 2018 Results on Feb 26, 2019 Oct 06
Analysts lower EPS estimates to -US$0.37 Aug 21
First half earnings released Aug 13
Cumberland Pharmaceuticals Inc. to Report Q2, 2020 Results on Aug 11, 2020 Aug 06
New 90-day low - US$3.15 Jul 29 Shareholder Returns CPIX US Pharmaceuticals US Market 7D 18.4% 0.6% -0.4% 1Y 42.6% 10.0% 24.8%
See full shareholder returns
Return vs Market: CPIX exceeded the US Market which returned 23.9% over the past year.
Price Volatility Is CPIX's price volatile compared to industry and market? CPIX volatility CPIX Average Weekly Movement 29.1% Pharmaceuticals Industry Average Movement 10.5% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: CPIX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CPIX's weekly volatility has increased from 17% to 29% over the past year.
About the Company Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis.
Show more Cumberland Pharmaceuticals Inc. Fundamentals Summary How do Cumberland Pharmaceuticals's earnings and revenue compare to its market cap? CPIX fundamental statistics Market cap US$35.25m Earnings (TTM ) -US$10.87m Revenue (TTM ) US$36.79m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CPIX income statement (TTM ) Revenue US$36.79m Cost of Revenue US$6.14m Gross Profit US$30.65m Other Expenses US$41.52m Earnings -US$10.87m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.77 Gross Margin 83.31% Net Profit Margin -29.55% Debt/Equity Ratio 65.8%
How did CPIX perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/24 04:11 End of Day Share Price 2024/12/24 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Cumberland Pharmaceuticals Inc. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Andrew D'Silva B. Riley Securities, Inc. Irina Rivkind Koffler Duncan-Williams, Inc. David Windley Jefferies LLC
Show 3 more analysts 
